SCHEMBL23107237

SCHEMBL23107237

C=C1C(=O)O[C@H]2CC3=CCC[C@@H](C)[C@]3(C)C[C@@H]12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ XBP1 P17861 1/20 0.47
▸ MDM2 Q00987 1/20 0.47
▸ PTGS2 P35354 3/20 0.46
▸ PKM P14618 2/20 0.39
▸ RECQL P46063 1/20 0.39
▸ UBE2D3 P61077 1/20 0.39
▸ CYP3A4 P08684 3/20 0.37
▸ LMNA P02545 2/20 0.37
▸ TP53 P04637 2/20 0.37
▸ CYP2D6 P10635 2/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ STAT3 P40763 1/20 0.36
▸ NLRP3 Q96P20 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29379738 1.00 MAPT (0.47) MAPTRAB9AHTTNPC1XBP1
SCHEMBL14947797 1.00 MAPT (0.47) MAPTRAB9AHTTNPC1XBP1
SCHEMBL29383396 1.00 MAPT (0.47) MAPTRAB9AHTTNPC1XBP1
SCHEMBL24246322 1.00 MAPT (0.47) MAPTRAB9AHTTNPC1XBP1
SCHEMBL12620337 0.90 MAPT (0.42) MAPTRAB9AHTTNPC1XBP1
SCHEMBL24246301 0.75 CYP3A4 (0.43) MAPTRAB9AHTTNPC1XBP1
SCHEMBL23106842 0.75 CYP3A4 (0.43) MAPTRAB9AHTTNPC1XBP1
SCHEMBL29380255 0.75 CYP3A4 (0.43) MAPTRAB9AHTTNPC1XBP1
SCHEMBL24246204 0.75 SMN1; SMN2 (0.34) CYP2C19
SCHEMBL23106956 0.75 SMN1; SMN2 (0.34) CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018006-B2 Method of producing EPD and analogues thereof VAN HAAFTEN CAROLINE (NL) 2024-06-25 — — US disclosed
US-12018006-B2 Method of producing EPD and analogues thereof VAN HAAFTEN CAROLINE (NL) 2024-06-25 — — US disclosed
EP-3634954-B1 METHOD OF PRODUCING EPD AND ANALOGUES THEREOF VAN HAAFTEN CAROLINE (NL) 2022-02-09 — — EP disclosed
US-20210078965-A1 METHOD OF PRODUCING EPD AND ANALOGUES THEREOF VAN HAAFTEN CAROLINE (NL) 2021-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018006-B2 Method of producing EPD and analogues thereof EPX, EPB41, ERG28 MAPT 4458/4885RAB9A 644/4885HTT 4693/4885
US-20210078965-A1 METHOD OF PRODUCING EPD AND ANALOGUES THEREOF EPX, EPB41, ERG28 MAPT 4458/4885RAB9A 644/4885HTT 4693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback